Globus Medical Reports Third Quarter 2024 Results

GMED 11.05.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-11-05
Name of Upcoming Event:Conference Call
Full Press ReleaseSEC FilingsOur GMED Tweets

About Gravity Analytica

Recent News

  • 01.08.2025 - Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results
  • 11.22.2024 - Globus Medical Launches ExcelsiusHub™ Navigation System

Recent Filings

  • 01.14.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.10.2025 - 144 Report of proposed sale of securities
  • 01.08.2025 - EX-99.1 EX-99.1
PDF Version

AUDUBON, Pa.,Nov. 05, 2024(GLOBE NEWSWIRE) --Globus Medical, Inc.(NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter endedSeptember 30, 2024.

  • Worldwide net sales were$625.7 million, an increase of 63.1%
  • GAAP net income for the quarter was$51.8 million
  • GAAP diluted earnings per share (“EPS”) was$0.38and non-GAAP diluted EPS was$0.83
  • Non-GAAP adjusted EBITDA was$193.7 million, or 31.0% of net sales

“Our third quarter results reflect the enduring strength of our business. We’ve continued to deliver on our business objectives to drive sales growth, launch new products, and execute our integration plans, all while delivering strong financial results,” saidDan Scavilla, President and Chief Executive Officer. “We strive to move with a sense of urgency to deliver innovations that improve the quality of life of patients with musculoskeletal disorders.”

“The execution of our objectives is clearly visible in our third quarter financial results,” commentedKeith Pfeil, COO-CFO. “We delivered meaningful sales growth across our portfolio and generated strong earnings growth, all of which delivered record operating and free cash results in the quarter, while continuing to invest for the long-term. We look to close the remainder of the year with momentum and build upon this as we enter into 2025.”

Worldwide net sales for the third quarter of 2024 were$625.7 million, an as-reported increase of 63.1% over the third quarter of 2023.U.S.net sales for the third quarter of 2024 increased by 60.3% compared to the third quarter of 2023. International net sales increased by 74.8% over the third quarter of 2023 on an as-reported basis, and increased by 76.2% on a constant currency basis.Net Salesincreases were driven by the addition ofNuVasive, as well as increased volume of spine product sales and enabling technology products and services.

GAAP net income for the third quarter of 2024 was$51.8 million, an increase over the same period in the prior year. Diluted EPS for the third quarter was$0.38, compared to$0.01for the third quarter of 2023. The GAAP net income increase was primarily driven by strong sales, as well as a decrease in acquisition related costs in the current period as compared to the prior period. Non-GAAP diluted EPS for the third quarter of 2024, which excludes, among other costs, both acquisition-related and restructuring costs, was$0.83, compared to$0.57in the third quarter of 2023, an increase of 45.2%.

Net cash provided by operating activities was$203.7 million, and non-GAAP free cash flow was$161.7 millionfor the third quarter of 2024.

As ofSeptember 30, 2024, we no longer include acquisition of in-process research and development as an adjustment to non-GAAP Adjusted EBITDA or non-GAAP net income.

2024Annual Guidance

The Company raised its guidance for full year 2024 revenue to be in the range of$2.49to$2.50 billion, and non-GAAP fully diluted earnings per share to be in the range of$2.90to$3.00. The revised non-GAAP fully diluted earnings per share guidance includes a$0.09impact of no longer adjusting for the acquisition of in-process research and development.

Conference Call Information

Globus Medicalwill hold a teleconference to discuss its third quarter 2024 results with the investment community at4:30 p.m. Eastern Timetoday. Participants may access the conference call live via webcast on the Investors page of Globus Medical’s website athttp://www.investors.globusmedical.com/news-events/events-webcasts.

To participate via telephone, please register in advance at thislink. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. The audio archive will be available after the call on the Investor page of theGlobus Medicalwebsite.

AboutGlobus Medical, Inc.

Based inAudubon, Pennsylvania,Globus Medical, Inc.was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed atwww.globusmedical.com.

Non-GAAP Financial Measures

To supplement our financial statements prepared in accordance withU.S.generally accepted accounting principles (“U.S. GAAP”), management uses certain non-GAAP financial measures. For example, non-GAAP Adjusted EBITDA, which represents net income before interest income, net and other non-operating expenses, provision for income taxes, depreciation and amortization, stock-based compensation expense, provision for litigation, merger and acquisition related costs, restructuring related costs, certain foreign currency acquisition-related impacts, and gains and losses from strategic investments, is useful as an additional measure of operating performance, and particularly as a measure of comparative operating performance from period to period, as it is reflective of changes in pricing decisions, cost controls and other factors that affect operating performance, and it removes the effect of our capital structure, asset base, income taxes and interest income and expense. As ofSeptember 30, 2024, we no longer include acquisition of in-process research and development as an adjustment to non-GAAP Adjusted EBITDA. Our management also uses non-GAAP Adjusted EBITDA for planning purposes, including the preparation of our annual operating budget and financial projections. Provision for litigation represents costs incurred for litigation settlements or unfavorable verdicts when the loss is known or considered probable and the amount can be reasonably estimated, or in the case of a favorable settlement, when income is realized. Merger and acquisition related costs represents the change in fair value of business-acquisition-related contingent consideration; costs related to integrating recently acquired businesses, including but not limited to costs to exit or convert contractual obligations, severance, retention bonus, duplicative costs and information system conversion; and specific costs related to the consummation of the acquisition process such as banker fees, legal fees, and other acquisition related professional fees. Restructuring related costs include severance, retention bonus, accelerated stock-based compensation expense, and costs associated with consolidating facilities. We also adjusted for certain foreign currency impacts related to the acquisition costs and gains/losses on strategic investments within other assets as we believe these impacts are not a measure of our operating performance.

In addition, for the period endedSeptember 30, 2024and for other comparative periods, we are presenting non-GAAP net income and non-GAAP Diluted Earnings Per Share, which represent net income and diluted earnings per share excluding the provision for litigation, amortization of intangibles, merger and acquisition related costs, restructuring related costs, certain foreign currency impacts, gains and losses from strategic investments, the impact of dilution attributable to the Convertible Notes, and the tax effects of all of the foregoing adjustments. As ofSeptember 30, 2024, we no longer include acquisition of in-process research and development as an adjustment to non-GAAP net income. We also present Non-GAAP gross profit, which excludes the impacts of any inventory acquisition-related costs within cost of goods sold. The tax effect adjustment represents the tax effect of the pre-tax non-GAAP adjustments excluded from non-GAAP net income. The tax impact of the non-GAAP adjustments is calculated based on the consolidated effective tax rate on a GAAP basis, applied to the non-GAAP adjustments, unless the underlying item has a materially different tax treatment, in which case the estimated tax rate applicable to the adjustment is used. We believe these non-GAAP measures are also useful indicators of our operating performance, and particularly as additional measures of comparative operating performance from period to period as they remove the effects of the foregoing items, which we believe are not reflective of underlying business trends. Additionally, for the period endedSeptember 30, 2024and for other comparative periods, we also define the non-GAAP measure of free cash flow as the net cash provided by operating activities, adjusted for the impact of restricted cash, less the cash impact of purchases of property and equipment. We believe that this financial measure provides meaningful information for evaluating our overall financial performance for comparative periods as it facilitates an assessment of funds available to satisfy current and future obligations and fund acquisitions. Furthermore, the non-GAAP measure of constant currency net sales growth is calculated by translating current year net sales at the same average exchange rates in effect during the applicable prior year period. We believe constant currency net sales growth provides insight to the comparative increase or decrease in period net sales, in dollar and percentage terms, excluding the effects of fluctuations in foreign currency exchange rates.

Non-GAAP adjusted EBITDA, non-GAAP net income, non-GAAP diluted earnings per share, non-GAAP gross profit, free cash flow and constant currency net sales growth are not calculated in conformity withU.S.GAAP. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for financial measures prepared in accordance withU.S.GAAP. These measures do not include certain expenses that may be necessary to evaluate our liquidity or operating results. Our definitions of non-GAAP adjusted EBITDA, non-GAAP net income, non-GAAP diluted earnings per share, non-GAAP gross profit, free cash flow and constant currency net sales growth may differ from that of other companies and therefore may not be comparable.

Safe Harbor Statements

All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, the risks and costs associated with the integration of theNuVasivebusiness and our ability to successfully integrate and achieve anticipated synergies with the integration, health epidemics, pandemics and similar outbreaks, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with theU.S. Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with theU.S. Securities and Exchange Commission. These documents are available atwww.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

GLOBUS MEDICAL, INC.AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF INCOME(unaudited)

Three Months EndedNine Months Ended
September 30,September 30,
(In thousands, except per share amounts)2024202320242023
Net sales$625,705$383,639$1,862,062$951,942
Cost of Sales and Operating expenses:
Cost of sales (exclusive of amortization of intangibles)270,515135,390772,042282,688
Research and development35,38029,329130,34671,758
Selling, general and administrative240,738156,206727,567398,691
Provision for litigation, net(676)2,924628184
Amortization of intangibles30,07613,76189,46122,909
Acquisition-related costs(3,617)45,62512,53552,693
Restructuring costs5,191—23,766—
Operating income/(loss)48,098404105,717123,019
Other income/(expense), net
Interest income/(expense), net(775)7,920(5,004)22,711
Foreign currency transaction gain/(loss)10,279(5,314)(5,795)(5,649)
Other income/(expense)(570)(475)1,137318
Total other income/(expense), net8,9342,131(9,662)17,380
Income/(loss) before income taxes57,0322,53596,055140,399
Income tax provision/(benefit)5,1961,53719,57632,560
Net income/(loss)$51,836$998$76,479$107,839
Other comprehensive income/(loss), net of tax:
Unrealized gain/(loss) on marketable securities9122,6411,7836,979
Foreign currency translation gain/(loss)3,976(2,310)1,446(1,085)
Total other comprehensive income/(loss), net of tax4,8883313,2295,894
Comprehensive income/(loss)$56,724$1,329$79,708$113,733
Earnings per share:
Basic$0.38$0.01$0.56$1.03
Diluted$0.38$0.01$0.56$0.98
Weighted average shares outstanding:
Basic135,615113,537135,390104,762
Diluted138,062115,245137,245110,058

GLOBUS MEDICAL, INC.AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS(unaudited)

September 30,December 31,
(In thousands, except share and per share values)20242023
ASSETS
Current assets:
Cash and cash equivalents$622,766$467,292
Short-term marketable securities71,94050,497
Accounts receivable, net of allowances of$23,542and$8,934, respectively588,047503,235
Inventories717,703848,135
Prepaid expenses and other current assets50,92444,580
Income taxes receivable5,1491,635
Total current assets2,056,5291,915,374
Property and equipment, net of accumulated depreciation of$505,982and$425,695, respectively567,822586,932
Operating lease right of use assets52,82459,931
Long-term marketable securities12,29775,428
Intangible assets, net842,778924,603
Goodwill1,431,6661,434,540
Other assets76,64378,590
Deferred income taxes45,48510,685
Total assets$5,086,044$5,086,083
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable$57,537$56,671
Accrued expenses255,260240,460
Operating lease liabilities11,04011,967
Income taxes payable4,1743,845
Senior convertible notes437,142—
Business acquisition liabilities32,11061,035
Deferred revenue20,80218,369
Total current liabilities818,065392,347
Business acquisition liabilities, net of current portion81,74878,323
Operating lease liabilities86,37691,037
Senior convertible notes—417,400
Deferred income taxes and other tax liabilities7,47584,421
Other liabilities22,98324,596
Total liabilities1,016,6471,088,124
Equity:
Class A common stock;$0.001par value. Authorized 500,000,000 shares; issued and outstanding 113,474,233 and 113,905,565 shares atSeptember 30, 2024andDecember 31, 2023, respectively113114
Class B common stock;$0.001par value. Authorized 275,000,000 shares; issued and outstanding 22,430,097 and 22,430,097 shares atSeptember 30, 2024andDecember 31, 2023, respectively2222
Additional paid-in capital2,949,9172,870,749
Accumulated other comprehensive income/(loss)(6,963)(10,192)
Retained earnings1,126,3081,137,266
Total equity4,069,3973,997,959
Total liabilities and equity$5,086,044$5,086,083

GLOBUS MEDICAL, INC.AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(unaudited)

Nine Months Ended
September 30,
(In thousands)20242023
Cash flows from operating activities:
Net income$76,479$107,839
Adjustments to reconcile net income to net cash provided by operating activities:
Acquired in-process research and development12,613—
Depreciation and amortization185,79673,571
Amortization of premiums on marketable securities(119)730
Provision for excess and obsolete inventory16,1946,700
Amortization of inventory fair value step up168,09719,065
Amortization of 2025 Note fair value step up19,973—
Stock-based compensation expense42,28440,297
Allowance for expected credit losses15,6674,284
Change in fair value of business acquisition liabilities8,6084,431
Change in deferred income taxes(92,723)(45,990)
(Gain)/loss on disposal of assets, net2,6871,466
Payment of business acquisition-related liabilities(18,084)(2,370)
Net (gain)/loss from foreign currency adjustment(2,354)—
(Increase) decrease in:
Accounts receivable(100,545)(36,953)
Inventories(17,973)(58,978)
Prepaid expenses and other assets(3,108)(1,280)
Increase (decrease) in:
Accounts payable1,294(7,952)
Accrued expenses and other liabilities38920,579
Income taxes payable/receivable(4,876)13,386
Net cash provided by/(used in) operating activities310,299138,825
Cash flows from investing activities:
Purchases of marketable securities(13,366)(100,643)
Maturities of marketable securities47,746214,430
Sales of marketable securities9,644219,987
Purchases of property and equipment(98,318)(55,393)
Acquisition of businesses, net of cash acquired and purchases of intangible and other assets(17,635)(296,028)
Net cash provided by/(used in) investing activities(71,929)(17,647)
Cash flows from financing activities:
Payment of business acquisition-related liabilities(37,003)(5,908)
Net proceeds from exercise of stock options41,15611,357
Payments related to tax withholdings for share-based compensation(6,795)—
Repurchase of common stock(84,787)—
Net cash provided by/(used in) financing activities(87,429)5,449
Effect of foreign exchange rates on cash4,5332,527
Net increase/(decrease) in cash and cash equivalents155,474129,154
Cash and cash equivalents at beginning of period467,292150,466
Cash and cash equivalents at end of period$622,766$279,620
Supplemental disclosures of cash flow information:
Income taxes paid, net$117,474$65,171
Non-cash investing and financing activities:
Equity issued in conjunction with the NuVasive Merger$—$2,153,860
Accrued purchases of property and equipment$4,802$5,971

Supplemental Financial Information

Net Salesby Product Category:

Three Months EndedNine Months Ended
September 30,September 30,
(In thousands)2024202320242023
Musculoskeletal Solutions$587,402$355,978$1,755,011$864,440
Enabling Technologies38,30327,661107,05187,502
Total net sales$625,705$383,639$1,862,062$951,942

Liquidity and Capital Resources:

September 30,December 31,
(In thousands)20242023
Cash and cash equivalents$622,766$467,292
Short-term marketable securities71,94050,497
Long-term marketable securities12,29775,428
Total cash, cash equivalents and marketable securities$707,003$593,217

The following tables reconcile GAAP to Non-GAAP financial measures.

As ofSeptember 30, 2024, we no longer include Acquisition of in-process research and development as an adjustment to the non-GAAP financial measures. As previously disclosed, the Company incurred$12.6 millionin the nine months endedSeptember 30, 2024for the Acquisition of in-process research and development, which, when it was previously included, resulted in a year-to-date impact of 0.7% on Adjusted EBITDA as a percentage of net sales and$0.09on Non-GAAP diluted earnings per share.

Non-GAAP Adjusted EBITDA Reconciliation Table:

Three Months EndedNine Months Ended
September 30,September 30,
(In thousands, except percentages)2024202320242023
Net income/(loss)$51,836$998$76,479$107,839
Interest (income)/expense, net775(7,920)5,004(22,711)
Provision for income taxes5,1961,53719,57632,560
Depreciation and amortization66,94737,388185,79673,571
EBITDA124,75432,003286,855191,259
Stock-based compensation expense11,3569,87736,53027,418
Provision for litigation, net(676)2,924628184
Merger and acquisition-related costs(1)61,16064,883185,16072,067
Net (gain) loss from strategic investments—268(267)268
Non-cash acquisition-related foreign currency impacts(8,912)2,898(2,354)2,898
Restructuring costs6,009—31,542—
Adjusted EBITDA$193,691$112,852$538,094$294,094
Net income/(loss) as a percentage of net sales8.3%0.3%4.1%11.3%
Adjusted EBITDA as a percentage of net sales31.0%29.4%28.9%30.9%

(1)Merger and acquisition-related costs represent certain costs associated with acquisitions. These costs, presented on a before-tax effect basis, include the following:

Three Months EndedNine Months Ended
September 30,September 30,
2024202320242023
(In thousands)
Amortization of inventory fair value step up$60,756$19,065$168,097$19,065
Change in fair value of business acquisition liabilities(4,133)1,4708,6104,576
Employee-related costs3,57434,0045,03134,004
Other acquisition-related costs(a)96310,3443,42214,422
Merger and acquisition-related costs$61,160$64,883$185,160$72,067
(a) Primarily comprised of legal fees, investment banking and consulting fees.

Non-GAAP Net Income Reconciliation Table:

Three Months EndedNine Months Ended
September 30,September 30,
(In thousands)2024202320242023
Net income/(loss)$51,836$998$76,479$107,839
Provision for litigation, net(676)2,924628184
Amortization of intangibles30,07613,76189,46122,909
Merger and acquisition -related costs(1)61,16064,883185,16072,067
Non-cash acquisition-related foreign currency impacts(8,912)2,898(2,354)2,898
Restructuring Costs6,009—31,542—
Net gain/(loss) on strategic investments—268(267)268
Tax effect of adjusting items(25,507)(20,201)(78,454)(23,260)
Non-GAAP net income/(loss)$113,986$65,531$302,195$182,905

(1)see footnote 1 to the Non-GAAP Adjusted EBITDA Reconciliation Table above for the detail of these costs

Non-GAAP Gross Profit Reconciliation Table:

Three Months EndedNine Months Ended
September 30,September 30,
(In thousands)2024202320242023
Net Sales$625,705$383,639$1,862,062$951,942
Cost of Sales (exclusive of amortization of intangibles)270,515135,390772,042282,688
Amortization of Intangibles23,8419,52666,59315,408
Gross Profit331,349238,7231,023,427653,846
Amortization of inventory fair value step up60,75619,065168,09719,065
Amortization of Intangibles23,8419,52666,59315,408
Adjusted Gross Profit$415,946$267,314$1,258,117$688,319
Gross Profit % ofNet Sales53.0%62.2%55.0%68.7%
Adjusted Gross Profit % ofNet Sales66.5%69.7%67.6%72.3%

Non-GAAP Diluted Earnings Per Share Reconciliation Table:

Three Months EndedNine Months Ended
September 30,September 30,
(In thousands)2024202320242023
Diluted earnings per share, as reported$0.38$0.01$0.56$0.98
Dilution attributable to Convertible Notes———0.03
Provision for litigation, net(0.00)0.03—0.03
Amortization of intangibles0.220.120.650.22
Merger and acquisition -related costs(1)0.440.561.350.68
Net (gain) loss from strategic investments——(0.00)—
Non-cash acquisition-related foreign currency impacts(0.06)0.03(0.02)0.03
Restructuring costs0.04—0.23—
Tax effect of adjusting items(0.18)(0.18)(0.57)(0.22)
Non-GAAP diluted earnings per share$0.83$0.57$2.20$1.75

*amounts might not add due to rounding(1)see footnote 1 to the Non-GAAP Adjusted EBITDA Reconciliation Table above for the detail of these costs

Non-GAAP Free Cash Flow Reconciliation Table:

Three Months EndedNine Months Ended
September 30,September 30,
(In thousands)2024202320242023
Net cash provided by operating activities$203,655$50,484$310,299$138,825
Purchases of property and equipment(41,952)(21,534)(98,318)(55,393)
Free cash flow$161,703$28,950$211,981$83,432

Non-GAAPNet Saleson a Constant Currency Basis Comparative Table:

Three Months EndedReportedCurrencyImpact onConstantCurrency
September 30,Net SalesCurrentNet Sales
(In thousands, except percentages)20242023GrowthPeriod Net SalesGrowth
United States$495,789$309,31560.3%$—60.3%
International129,91674,32474.8%(1,030)76.2%
Total net sales$625,705$383,63963.1%$(1,030)63.4%

Nine Months EndedReportedCurrencyImpact onConstantCurrency
September 30,Net SalesCurrentNet Sales
(In thousands, except percentages)20242023GrowthPeriod Net SalesGrowth
United States$1,478,174$788,92487.4%$—87.4%
International383,888163,018135.5%(6,600)139.5%
Total net sales$1,862,062$951,94295.6%$(6,600)96.3%

The following table reconciles previously disclosed Non-GAAP fully diluted earnings per share guidance to current Non-GAAP fully diluted earnings per share guidance.

Non-GAAP Fully Diluted Earnings per Share Guidance Adjustments:

Year Ended
December 31, 2024
Low EndHigh End
Previously disclosed non-GAAP fully diluted earnings per share guidance$2.80$2.90
Removal of Acquisition of in-process research and development adjustment(0.09)(0.09)
Increase to guidance0.190.19
Current non-GAAP fully diluted earnings per share guidance$2.90$3.00

Contact:Brian KearnsSenior Vice President, Business Development and Investor RelationsPhone: (610) 930-1800Email:investors@globusmedical.comwww.globusmedical.com

Primary Logo

Source: Globus Medical

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com